Manrai M, Tilak TVSVGK, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World J Gastroenterol 2021; 27(39): 6572-6589 [PMID: 34754153 DOI: 10.3748/wjg.v27.i39.6572]
Corresponding Author of This Article
Manish Manrai, MBBS, MD, Professor, Department of Internal Medicine, Armed Forces Medical College, Solapur Road, Pune 411040, Maharashtra, India. manishmanrai@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 21, 2021; 27(39): 6572-6589 Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6572
Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
Manish Manrai, T V S V G K Tilak, Saurabh Dawra, Sharad Srivastava, Anupam Singh
Manish Manrai, T V S V G K Tilak, Department of Internal Medicine, Armed Forces Medical College, Pune 411040, Maharashtra, India
Saurabh Dawra, Sharad Srivastava, Department of Internal Medicine, Command Hospital, Pune 411040, Maharashtra, India
Anupam Singh, Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh 160011, India
Author contributions: Manrai M conceptualized the review and with Tilak TVSVGK, Dawra S was involved with resources, formal analysis, data curation, writing, review, and editing; Srivastava S was involved with resources and analysis; Singh A was involved with review and editing.
Conflict-of-interest statement: The authors have no conflict-of-interest for this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Manish Manrai, MBBS, MD, Professor, Department of Internal Medicine, Armed Forces Medical College, Solapur Road, Pune 411040, Maharashtra, India. manishmanrai@yahoo.com
Received: January 28, 2021 Peer-review started: January 28, 2021 First decision: May 2, 2021 Revised: May 9, 2021 Accepted: August 16, 2021 Article in press: August 16, 2021 Published online: October 21, 2021 Processing time: 264 Days and 13.9 Hours
Abstract
Pancreatic carcinoma (PC) is one of the leading causes of cancer-related deaths worldwide. Despite early detection and advances in therapeutics, the prognosis remains dismal. The outcome and therapeutic approach are dependent on the stage of PC at the time of diagnosis. The standard of care is surgery, followed by adjuvant chemotherapy. The advent of newer drugs has changed the landscape of adjuvant therapy. Moreover, recent trials have highlighted the role of neoadjuvant therapy and chemoradiotherapy for resectable and borderline resectable PC. As we progress towards a better understanding of tumor biology, genetics, and microenvironment, novel therapeutic strategies and targeted agents are now on the horizon. We have described the current and emerging therapeutic strategies in PC.
Core Tip: An improved understanding of the natural history of pancreatic carcinoma, genetics, and tumor biology has highlighted the role of novel therapeutic strategies. However, despite recent advances in the management of pancreatic carcinoma, the prognosis remains poor. We have attempted to conceptualize the current therapeutic strategies in light of recent advances.
